All In Biotech

Drug Trial Radar · NCT01591785

Treatment of Staphylococcus Aureus Colonization in Hand Eczema

An Investigator-Initiated Study: Treatment of Staphylococcus Aureus Colonization in Hand Eczema Decreases Severity of Disease

Last checked: Nov 20, 2026Latest source record: Dec 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

60

Actual

Start

Jan 2012

Primary completion

Aug 2012

Study completion Aug 2012

Sponsor

Lead sponsor
Gary GoldenbergAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 4, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Atopic dermatitis is a chronic disease characterized by itching and eczematous lesions. In adults, eczema commonly localizes to the hands or feet. Several studies have implicated bacterial contamination, especially with Staphylococcus aureus (S. aureus), to be a factor in atopic dermatitis, as infection with this bacteria correlates with disease severity. No trial to date has investigated how to treat S. aureus infection in adults with hand or hand/foot dermatitis. Using retapamulin ointment in the nose and on the hands or hands/feet, the investigators expect to have a significant clearance rate of s. aureus infection. The investigators believe that treating the bacterial infection along with treating the condition with a topical corticosteroid will significantly decrease the severity of hand/foot dermatitis in our study population.

Conditions

  • Hand Eczema
  • Foot Eczema

Interventions

  • Retapamulin 1% ointmentDrug

    Retapamulin 1% ointment for 5 days AND clobetasol propionate foam for 14 days

  • PlaceboDrug

    Placebo ointment for 5 days AND clobetasol propionate foam for 14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With PGA of 0 or 1Time frame: Day 15
  2. Number of Participants With PGA of 0 or 1Time frame: Day 28

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mount Sinai School of Medicine

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.